

**Supplementary Table 2. Baseline characteristics and clinical features of survivor and non-survivor group in the high APACHE-II score group ( $\geq 27.5$ )**

Characteristic	Survivor (n = 16)	Non-survivor (n = 78)	p value
Serum NGAL, ng/mL	797.5 (548.8–1,370.5)	759.5 (394.5–1,446.0)	0.864
APACHE-II score	30.0 (28.0–35.0)	33.0 (30.8–37.0)	0.040
SOFA score	14.0 (12.3–15.8)	15.0 (13.0–17.0)	0.137
Serum NGAL $\geq 805.0$ ng/mL	7 (43.8)	38 (48.7)	0.717
APACHE-II score $\geq 32.5$	5 (31.3)	45 (57.7)	0.053
SOFA score $\geq 14.5$	7 (43.8)	45 (57.7)	0.307
Age, yr	64.7 $\pm$ 12.4	65.5 $\pm$ 14.9	0.839
Body mass index, kg/m <sup>2</sup>	24.1 (20.9–27.9)	22.7 (20.7–24.9)	0.337
Male sex	7 (43.8)	46 (59.0)	0.263
C-reactive protein, mg/dL	13.3 (5.1–20.8)	11.1 (3.7–19.9)	0.782
Mechanical ventilation	10 (62.5)	70 (89.7)	0.013
Inotropics administration	14 (87.5)	68 (87.2)	1.000
Indication for CRRT initiation			
Sepsis	9 (56.3)	49 (62.8)	0.622
Postoperation	1 (6.3)	5 (6.4)	1.000
Cardiac	1 (6.3)	8 (10.3)	1.000
Pulmonary	1 (6.3)	1 (1.3)	0.313
Hepatic	2 (12.5)	7 (9.0)	0.647
Renal	2 (12.5)	3 (3.8)	0.200
Malignancy	0	3 (3.8)	1.000
Others	0	2 (2.6)	1.000
Comorbidities			
Diabetes mellitus	4 (25.0)	19 (24.4)	1.000
Hypertension	7 (43.8)	35 (44.9)	0.934
Chronic kidney disease	3 (18.8)	6 (7.7)	0.178
Cerebro-cardiovascular disease	5 (31.3)	18 (23.1)	0.529
Pulmonary disease	1 (6.3)	8 (10.3)	1.000
Liver disease	4 (25.0)	13 (16.7)	0.479
Dementia	0	1 (1.3)	1.000
Malignancy	6 (37.5)	17 (21.8)	0.208

Values are presented as median (interquartile range), number (%), or mean  $\pm$  SD.

APACHE-II, Acute Physiology and Chronic Health Evaluation-II; NGAL, neutrophil gelatinase-associated lipocalin; SOFA, Sequential Organ Failure Assessment; CRRT, continuous renal replacement therapy.